ATXS — Astria Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
Astria Therapeutics Inc (ATXS) is a biotechnology company listed on NASDAQ. It is led by Jill C. Milne Ph.D., based in 22 Boston Wharf Road, Boston, MA, United States, 02210, with about 78 employees. Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Latest reported ATXS revenue for 2025-09-30 was $706.0K. Net income was -$98.4M. ATXS currently screens at market cap $382.1M.
Use this ATXS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATXS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATXS SEC filings page. Lician reads the product cache first so this HTML stays unique to Astria Therapeutics Inc even when a live quote feed is slow.
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
ATXS Key Statistics
Market Cap
$382.06M
EPS
-$1.68
Revenue
$0.00
Net Income
-$94.26M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
78
ATXS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$94.26M | -$72.89M | -$51.83M | -$194.91M |
| EPS (Diluted) | -$1.68 | -$2.42 | -$3.55 | -$24.58 |
Total Assets
$342.36M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$59.82M
Operating Cash Flow
-$81.21M
Free Cash Flow
$0.00
Astria Therapeutics Inc Company Information
- Co-Founder, CEO, President & Director
- Jill C. Milne Ph.D.
- Headquarters
- 22 Boston Wharf Road, Boston, MA, United States, 02210
- Website
- www.astriatx.com
- Phone
- 617 349 1971
- IPO / Founded
- 2015-06-25
- Sector
- Healthcare
- Industry
- Biotechnology